Exact Sciences Corporation

EXAS

Healthcare

$104.91

$38.81

$104.98

52W RangeNear 52W High

Stock Timeline

Institutional Holders

0 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

918

Est. Sold Value

$93K

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Hold

Strong Buy

Hold

Analyst Targets

avg.

$106.30

vs Current ▲ +1.3% upside

Current$104.91

Low ~ High$105.00 ~ $118.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Mizuho

Neutral

$105.00

+0.09%

$102.35

Downgrade

2026-01-20

Evercore ISI Group

In-Line

$105.00

+0.09%

$101.61

Downgrade

2026-01-05

Stifel

Hold

$105.00

+0.09%

$101.29

Downgrade

2025-11-28

Canaccord Genuity

Hold

$105.00

+0.09%

$101.13

Downgrade

2025-11-25

Benchmark

Hold

N/A

$101.01

Downgrade

2025-11-24

1 / 53

Avg Target

$106.30

vs Current ▲ +1.3% upside

Hold

12 analysts

Strong Buy 1Hold 11

Low $105.00

Current $104.91

High $118.00

Firm	Position	Target	Upside	Close	Action	Date
Mizuho	Neutral	$105.00	+0.09%	$102.35	Downgrade	26.01.20
Evercore ISI Group	In-Line	$105.00	+0.09%	$101.61	Downgrade	26.01.05
Stifel	Hold	$105.00	+0.09%	$101.29	Downgrade	25.11.28
Canaccord Genuity	Hold	$105.00	+0.09%	$101.13	Downgrade	25.11.25
Benchmark	Hold	N/A	N/A	$101.01	Downgrade	25.11.24

1 / 53

Price Information

Previous Close$104.91

Open$104.93

Day Range$104.90 - $104.98

52-Week Range$38.81 - $104.98

1-Year Change135.44%

Trading Volume

Volume21,562,141

Avg Volume (3mo)2,473,639

Valuation

Market Cap20.0B

Book Value$12.58

Shares Outstanding190,888,211

Financials

Revenue (TTM)3.2B

Net Income-207,948,992

EPS$-1.10

EBITDA71.5M

Profitability

P/E Ratio-

P/B Ratio8.34

Return on Equity (ROE)-8.66%

Return on Assets (ROA)-1.59%

Profit Margin-6.40%

EV/EBITDA302.23

Beta1.44

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)-

Company Overview

Exact Sciences Corporation is a leading provider of cancer screening and diagnostic tests. Their main products include Cologuard for colorectal cancer screening and the Oncotype DX tests for breast and colon cancer recurrence risk. The company is focused on developing innovative solutions across the entire cancer care continuum, from risk assessment to recurrence monitoring.

P/B

8.34

High valuation

ROE

-8.7%

Net loss

Beta

1.44

Market Volatility

RSI(14)

AI-generated summary. Not investment advice.